{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:08:17Z","timestamp":1770822497223,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T00:00:00Z","timestamp":1266451200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1746-1596-5-13","type":"journal-article","created":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T14:14:52Z","timestamp":1266502492000},"source":"Crossref","is-referenced-by-count":15,"title":["The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas"],"prefix":"10.1186","volume":"5","author":[{"given":"Aylin Ege","family":"Gul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevinc Hallac","family":"Keser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagehan Ozdemir","family":"Barisik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilufer Onak","family":"Kandemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caglar","family":"Cak\u0131r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Sensu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimet","family":"Karadayi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,18]]},"reference":[{"issue":"5","key":"258_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1447-0756.2008.00796.x","volume":"34","author":"P Uharcek","year":"2008","unstructured":"Uharcek P: Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res. 2008, 34 (5): 776-83. 10.1111\/j.1447-0756.2008.00796.x.","journal-title":"J Obstet Gynaecol Res"},{"key":"258_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1525-1438.2007.00946.x","volume":"18","author":"FE Odicino","year":"2008","unstructured":"Odicino FE, Bignotti E, Rossi E, Pasinetti B, Tassi RA, Donzelli C, Falchetti M, Fontana P, Grigolato PG, Pecorelli S: HER-2\/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real time reverse transcription-polymerase chain reaction, and fluorescense in situ hybridization. Int J Gynecol. 2008, 18: 14-21.","journal-title":"Int J Gynecol"},{"key":"258_CR3","first-page":"2839","volume":"27","author":"M Benevolo","year":"2007","unstructured":"Benevolo M, Vocaturo A, Novelli F, Mariani L, Vocaturo G, Cianciulli AM, Marandino F, Perrone-Donnorso R, Giannarelli D, Natali PG, Mottolese M: Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing. Anticancer Research. 2007, 27: 2839-44.","journal-title":"Anticancer Research"},{"key":"258_CR4","first-page":"261","volume":"18","author":"M Brys","year":"2007","unstructured":"Brys M, Semczuk A, Rechberger T, Krajewska WM: Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium. Oncology Reports. 2007, 18: 261-5.","journal-title":"Oncology Reports"},{"key":"258_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijgo.2008.04.008","volume":"102","author":"AD Santin","year":"2008","unstructured":"Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S: Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2\/neu. Int J Gynecol Obstet. 2008, 102: 128-31. 10.1016\/j.ijgo.2008.04.008.","journal-title":"Int J Gynecol Obstet"},{"key":"258_CR6","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1111\/j.1525-1438.2006.00664.x","volume":"16","author":"JA Villella","year":"2006","unstructured":"Villella JA, Cohen S, Smith DH, Hibshoosh H, Hersman D: HER-2\/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer. 2006, 16: 1897-1902. 10.1111\/j.1525-1438.2006.00664.x.","journal-title":"Int J Gynecol Cancer"},{"key":"258_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","volume":"108","author":"TA Grushko","year":"2008","unstructured":"Grushko TA, Filiaci VL, Mundt AJ, Ridderstrale K, Olopade OI, Pleming GF: An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group study. Gynecol Oncol. 2008, 108: 3-9. 10.1016\/j.ygyno.2007.09.007.","journal-title":"Gynecol Oncol"},{"key":"258_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ygyno.2005.03.041","volume":"98","author":"AD Santin","year":"2005","unstructured":"Santin AD, Belone S, Stedum SV, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S: Determination of HER2\/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol. 2005, 98: 24-30. 10.1016\/j.ygyno.2005.03.041.","journal-title":"Gynecol Oncol"},{"key":"258_CR9","first-page":"115","volume":"22","author":"M Dahmoun","year":"2003","unstructured":"Dahmoun M, Backstrom T, Boman K, Cajander S: Apoptosis, proliferation, and hormone receptors in endometrial carcinoma: Results depending on methods of analysis. Int J Oncol. 2003, 22: 115-22.","journal-title":"Int J Oncol"},{"key":"258_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1046\/j.1365-2559.1998.00560.x","volume":"33","author":"JL Burton","year":"1988","unstructured":"Burton JL, Wells M: Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. Histopathology. 1988, 33: 297-303. 10.1046\/j.1365-2559.1998.00560.x.","journal-title":"Histopathology"},{"key":"258_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.prp.2007.01.003","volume":"203","author":"N Kapucuoglu","year":"2007","unstructured":"Kapucuoglu N, Aktepe F, Kaya H, Bircan S, Karahan N, \u00c7iri\u015f M: Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax and apoptotic index. Pathol Res Pract. 2007, 203: 153-62. 10.1016\/j.prp.2007.01.003.","journal-title":"Pathol Res Pract"},{"issue":"7","key":"258_CR12","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/cncr.21308","volume":"104","author":"AD Santin","year":"2005","unstructured":"Santin AD, Bellone S, Stedum SV, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S: Amplification of cerB-2 oncogene. A major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005, 104 (7): 1391-7. 10.1002\/cncr.21308.","journal-title":"Cancer"},{"key":"258_CR13","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/j.1048-891X.2004.14533.x","volume":"14","author":"N Macwhinnie","year":"2004","unstructured":"Macwhinnie N, Monaghan H: The use of p53, PTEN, and c-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. Int J Gynecol Cancer. 2004, 14: 938-46. 10.1111\/j.1048-891X.2004.14533.x.","journal-title":"Int J Gynecol Cancer"},{"key":"258_CR14","first-page":"823","volume":"26","author":"A Mariani","year":"2006","unstructured":"Mariani A, Sebo TJ, Cliby WA, Keeney GL, Riehle DL, Lesnick TG, Podratz KC: Role of Bcl-2 in endometrioid corpus cancer: An experimental study. Anticancer Res. 2006, 26: 823-8.","journal-title":"Anticancer Res"},{"issue":"4","key":"258_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00004347-200210000-00007","volume":"21","author":"\u00d6 Bozdo\u011fan","year":"2002","unstructured":"Bozdo\u011fan \u00d6, Atasoy P, Erekul S, Bozdo\u011fan N, Bayram Ml: Apoptosis-related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium. Int J Gynecol Pathol. 2002, 21 (4): 375-82. 10.1097\/00004347-200210000-00007.","journal-title":"Int J Gynecol Pathol"},{"key":"258_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ygyno.2005.07.124","volume":"100","author":"CA Livasy","year":"2006","unstructured":"Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA: EGFR expression and HER2\/neu overexpression\/amplification in endometrial carcinosarcoma. Gynecol Oncol. 2006, 100: 101-6. 10.1016\/j.ygyno.2005.07.124.","journal-title":"Gynecol Oncol"},{"key":"258_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/BF02505331","volume":"259","author":"J Backe","year":"1997","unstructured":"Backe J, Gassel AM, Krebs S, M\u00fcller T, Caffier H: Immunohistochemically detected HER\/neu-expression and prognosis in endometrial carcinoma. Arch Gynecol Obstet. 1997, 259: 189-95. 10.1007\/BF02505331.","journal-title":"Arch Gynecol Obstet"},{"key":"258_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1046\/j.1440-1827.2003.01509.x","volume":"53","author":"C Suzuki","year":"2003","unstructured":"Suzuki C, Matsumato T, Sonouoe H, Arakawa A, Furugen Y, Kinoshita K: Prognostic significance of the infiltrative pattern invasion in endometrioid adenocarcinoma of the endometrium. Pathol Int. 2003, 53: 495-500. 10.1046\/j.1440-1827.2003.01509.x.","journal-title":"Pathol Int"},{"issue":"4","key":"258_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/modpathol.3880062","volume":"13","author":"S Kounelis","year":"2000","unstructured":"Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW: Immunohistochemical profile of endometrial adenocarcinoma: A study of 61 cases and review of the literature. Mod Pathol. 2000, 13 (4): 379-88. 10.1038\/modpathol.3880062.","journal-title":"Mod Pathol"},{"issue":"2","key":"258_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0304-3835(06)80025-X","volume":"98","author":"P Kohlberger","year":"1996","unstructured":"Kohlberger P, Loesch A, Koelbl H, Breitenecker G, Kainz C, Gitsch G: Prognostic value of immunohistochemically detected HER-2\/neu oncoprotein in endometrial cancer. Cancer Lett. 1996, 98 (2): 151-5.","journal-title":"Cancer Lett"},{"issue":"1","key":"258_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0301-2115(00)00562-5","volume":"98","author":"PJ Coronado","year":"2001","unstructured":"Coronado PJ, Vidart JA, Lopes-asenjo JA, Fasero M, Furio-bacete V, Magrina J, Escudero M: P53 overexpression predicts endometrial carcinoma recurrence beter than HER-2\/neu overexpression. Eur J Obstet Gynecol Reprod Biol. 2001, 98 (1): 103-8. 10.1016\/S0301-2115(00)00562-5.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"258_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1006\/gyno.1994.1092","volume":"53","author":"MA Khalifa","year":"1994","unstructured":"Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW: Expression of EGFR, HER-2\/neu, p53, and PCNA in endometriod serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994, 53 (1): 84-92. 10.1006\/gyno.1994.1092.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"258_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/00004347-199904000-00007","volume":"18","author":"CD Rolitsky","year":"1999","unstructured":"Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH: HER-2\/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999, 18 (2): 138-43.","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"258_CR24","first-page":"95","volume":"79","author":"RM Bigsby","year":"1992","unstructured":"Bigsby RM, Li AX, Bomalaski J, Stehman FB, Look KY, Sutton GP: Immunohistochemical study of HER-2\/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol. 1992, 79 (1): 95-100.","journal-title":"Obstet Gynecol"},{"issue":"1 Pt 1","key":"258_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0002-9378(91)90615-X","volume":"164","author":"A Berchuck","year":"1991","unstructured":"Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, Bast RC: Overexpression of HER-2\/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol. 1991, 164 (1 Pt 1): 15-21.","journal-title":"Am J Obstet Gynecol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1746-1596-5-13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1746-1596-5-13\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1746-1596-5-13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T18:51:47Z","timestamp":1548096707000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/1746-1596-5-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["258"],"URL":"https:\/\/doi.org\/10.1186\/1746-1596-5-13","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,18]]},"article-number":"13"}}